Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. · 2018
Read Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. by Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5840207.txt.
Description
Fleming and co-authors survey ways to disarm myeloid-derived suppressor cells in cancer. Their review appeared in Frontiers in Immunology. These immature myeloid cells gather in tumors and mute the immune response. Their numbers track with worse outcomes and failed immunotherapy.
The cells starve T cells of key amino acids. They flood the scene with suppressive signals and nitric oxide. They also build blood vessels and prepare distant soil for metastasis. Trials now test three counters: blocking their suppression, stopping their travel, and wiping them out. Pairing those moves with checkpoint drugs is the larger hope.
Catalog record
| CREATOR | Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |